Targeting PAD4: A Promising Strategy to Combat β-Cell Loss in Type 1 Diabetes
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26136113 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hsu Lin Kang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Biology and Experimental Dental Research, Faculty of Dentistry, University of Szeged, 6703 Szeged, Hungary. Hauptthemen laut MEDLINE: Protein-Arginine Deiminase Type 4, Diabetes Mellitus, Type 1, Insulin-Secreting Cells, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bolyai János postdoctoral research fellow fund, Incubation Competence Centre of the Centre of Excellence for Interdisciplinary Research, Development, and Innovation of the University of Szeged.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Peptidylarginine deiminase 4 (PAD4) catalyzes protein citrullination, a post-translational modification implicated in type 1 diabetes mellitus (T1DM). This study examined PAD4 expression and activity in the pancreas of streptozotocin (STZ)-induced diabetic Wistar rats. Animals were divided into three groups: (A) STZ-induced diabetic rats (60 mg/kg, i.p.), (B) non-diabetic controls, and (C) diabetic rats treated with Cl-amidine (5 mg/kg), a pan-PAD inhibitor, from week six post-induction. Analyses included PAD4 mRNA and protein expression, citrullinated histone H3 (CitH3), calcium concentration, and neutrophil elastase activity. Diabetic rats exhibited increased PAD4 expression, CitH3 levels, and NETosis markers, alongside reduced pancreatic calcium, suggesting calcium consumption during PAD4 activation. Cl-amidine treatment attenuated NETosis. These results implicate PAD4 in T1DM pathogenesis via NETosis and support the utility of STZ-induced diabetic rats as a model for PAD4-targeted studies. Cl-amidine may represent a promising therapeutic approach to reduce pancreatic inflammation in T1DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Biology and Experimental Dental Research, Faculty of Dentistry, University of Szeged, 6703 Szeged, Hungary.
- Department of Internal Medicine, Albert Szent-Györgyi Medical School, University of Szeged, 6703 Szeged, Hungary.
ORCID-Profile: Tamás Várkonyi
Förderung
- Bolyai János postdoctoral research fellow fund
- Incubation Competence Centre of the Centre of Excellence for Interdisciplinary Research, Development, and Innovation of the University of Szeged
Zitieren
APA
Kang, H. L., Szász, A., Valkusz, Z., Várkonyi, T., Pósa, A., & Kupai, K. (2025). Targeting PAD4: A Promising Strategy to Combat β-Cell Loss in Type 1 Diabetes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136113
Vancouver
Kang HL, Szász A, Valkusz Z, Várkonyi T, Pósa A, Kupai K. Targeting PAD4: A Promising Strategy to Combat β-Cell Loss in Type 1 Diabetes. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136113
BibTeX
@article{Kang2025,
author = {Kang, Hsu Lin and Szász, András and Valkusz, Zsuzsanna and Várkonyi, Tamás and Pósa, Anikó and Kupai, Krisztina},
title = {Targeting PAD4: A Promising Strategy to Combat β-Cell Loss in Type 1 Diabetes},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26136113}
}
EUVIMED